AbbVie initiates trial for lutikizumab in moderate to severe atopic dermatitis
AbbVie has initiated a clinical trial to evaluate the effectiveness and safety of lutikizumab for moderate to severe atopic dermatitis. The trial is structured into multiple substudies over a total duration of 52 weeks, featuring a randomized, open-label design.